PTEN expression and mutations in <i>TSC1</i>, <i>TSC2</i> and <i>MTOR</i> are associated with response to rapalogs in patients with renal cell carcinoma
Juan María Roldán‐Romero(European Bioinformatics Institute), Jesús García-Donás(Universidad San Pablo CEU), José Ángel Arranz(Hospital General Universitario Gregorio Marañón), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Daniel Castellano(Universidad Complutense de Madrid), Javier Lanillos(Spanish National Cancer Research Centre), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Juan Francisco Rodríguez-Moreno(Hospital Universitario HM Sanchinarro), Emilio Esteban(Hospital Universitario Central de Asturias), Gabrielle Couchy(Délégation Paris 5), Bruna Calsina(Spanish National Cancer Research Centre), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Javier Puente(Hospital Clínico San Carlos), María Santos(Spanish National Cancer Research Centre), Karin Tang(Hospital Universitario de Móstoles), Cristina Montero‐Conde(Spanish National Cancer Research Centre), Alberto Cascón(Spanish National Cancer Research Centre), Maarten Albersen, Núria Laínez(Complejo Hospitalario de Navarra), Ana Gutiérrez(University Hospital HM Puerta del Sur), Eduardo Caleiras(Spanish National Cancer Research Centre), Miguel Ángel Climent(Radboud University Nijmegen)
Cited by 29
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k